NASDAQ:VVOS - Vivos Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 43.37 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.37
▼ -0.53 (-5.96%)
1 month | 3 months | 12 months
Get New Vivos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VVOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VVOS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$12.00
▲ +43.37% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Vivos Therapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 43.37% upside from the last price of $8.37.
Buy
The current consensus among 2 investment analysts is to buy stock in Vivos Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2021Craig HallumInitiated CoverageBuy$12.00High
i
1/5/2021Roth CapitalInitiated CoverageBuy$12.00N/A
i
Rating by S. Henry at Roth Capital
(Data available from 4/18/2016 forward)
Vivos Therapeutics logo
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integrated Healthcare Network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate OSA. Vivos Therapeutics, Inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals. It caters to general dentists, medical doctors, myofunctional therapists, chiropractors, healthcare providers, and patients in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2007 and is based in Highlands Ranch, Colorado.
Read More

Today's Range

Now: $8.37
$8.30
$9.17

50 Day Range

MA: $7.56
$6.46
$9.67

52 Week Range

Now: $8.37
$5.64
$14.41

Volume

106,120 shs

Average Volume

202,837 shs

Market Capitalization

$152.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Vivos Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Vivos Therapeutics in the last year: Craig Hallum, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for VVOS.

What is the current price target for Vivos Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Vivos Therapeutics in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 43.4%. Roth Capital has the highest price target set, predicting VVOS will reach $12.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $12.00 for Vivos Therapeutics in the next year.
View the latest price targets for VVOS.

What is the current consensus analyst rating for Vivos Therapeutics?

Vivos Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VVOS will outperform the market and that investors should add to their positions of Vivos Therapeutics.
View the latest ratings for VVOS.

What other companies compete with Vivos Therapeutics?

How do I contact Vivos Therapeutics' investor relations team?

The company's listed phone number is 866 908 4867. The official website for Vivos Therapeutics is www.vivoslife.com.